| Title |
Repurposing metformin for the prevention of cancer and cancer recurrence
|
|---|---|
| Published in |
Diabetologia, August 2017
|
| DOI | 10.1007/s00125-017-4372-6 |
| Pubmed ID | |
| Authors |
Brandy M. Heckman-Stoddard, Andrea DeCensi, Vikrant V. Sahasrabuddhe, Leslie G. Ford |
| Abstract |
Multiple epidemiological studies have documented an association between metformin, used for treatment of type 2 diabetes, and reduced cancer incidence and mortality. Cell line models may not accurately reflect the effects of metformin in the clinical setting. Moreover, findings from animal model studies have been inconsistent, whilst those from more recent epidemiological studies have tempered the overall effect size. The purpose of this review is to examine metformin's chemopreventive potential by outlining relevant mechanisms of action, the most recent epidemiologic evidence, and recently completed and ongoing clinical trials. Although repurposing drugs with excellent safety profiles is an appealing strategy for cancer prevention and treatment in the adjuvant setting, there is no substitute for well-executed, large randomised clinical trials to define efficacy and determine the populations that are most likely to benefit from an intervention. Thus, enthusiasm remains for understanding the role of metformin in cancer through ongoing clinical research. |
X Demographics
The data shown below were collected from the profiles of 55 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 5 | 9% |
| United States | 5 | 9% |
| United Kingdom | 4 | 7% |
| Japan | 3 | 5% |
| Mexico | 2 | 4% |
| Ecuador | 2 | 4% |
| France | 2 | 4% |
| Australia | 1 | 2% |
| Netherlands | 1 | 2% |
| Other | 7 | 13% |
| Unknown | 23 | 42% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 40 | 73% |
| Practitioners (doctors, other healthcare professionals) | 8 | 15% |
| Scientists | 6 | 11% |
| Science communicators (journalists, bloggers, editors) | 1 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 201 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 201 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 30 | 15% |
| Student > Master | 27 | 13% |
| Researcher | 25 | 12% |
| Student > Ph. D. Student | 21 | 10% |
| Other | 16 | 8% |
| Other | 25 | 12% |
| Unknown | 57 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 49 | 24% |
| Biochemistry, Genetics and Molecular Biology | 30 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 19 | 9% |
| Agricultural and Biological Sciences | 15 | 7% |
| Immunology and Microbiology | 6 | 3% |
| Other | 15 | 7% |
| Unknown | 67 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 41. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2023.
All research outputs
#975,341
of 25,022,483 outputs
Outputs from Diabetologia
#516
of 5,330 outputs
Outputs of similar age
#19,940
of 322,655 outputs
Outputs of similar age from Diabetologia
#27
of 95 outputs
Altmetric has tracked 25,022,483 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,330 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.5. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,655 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.